ACM vs GNRC

ACM's Piotroski F-Score of 5/9 indicates stable financial health, though the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to both the Graham Number ($44.91) and intrinsic value ($33.18), currently priced at $97.08, suggesting overvaluation. Despite solid ROE of 28.09% and a history of consistent earnings beats (22 of 25 quarters), recent YoY earnings decline (-29.10%) and insider selling raise concerns. Analysts maintain a 'buy' recommendation with a $130.33 target, implying 24% upside, but weak technical trend (0/100) and bearish insider activity temper near-term optimism.

GNRC exhibits a severe disconnect between its current market price ($220.30) and its deterministic value markers, with a Piotroski F-Score of 4/9 indicating only stable health and a Graham Number of $52.11 suggesting massive overvaluation. While the balance sheet remains healthy with low debt and a strong current ratio, the company is facing significant headwinds including negative revenue growth (-11.60%) and a plummeting YoY EPS (-42.5%). The bearish sentiment is further reinforced by aggressive insider selling from the CEO and CFO and a very weak technical trend (10/100). Despite bullish analyst targets, the fundamental data suggests the stock is trading on speculative recovery rather than current performance.